PT2666014T - Utilização de glu-tubulina como um biomarcador da resposta farmacológica a furazanobenzimidazolos - Google Patents
Utilização de glu-tubulina como um biomarcador da resposta farmacológica a furazanobenzimidazolosInfo
- Publication number
- PT2666014T PT2666014T PT127004943T PT12700494T PT2666014T PT 2666014 T PT2666014 T PT 2666014T PT 127004943 T PT127004943 T PT 127004943T PT 12700494 T PT12700494 T PT 12700494T PT 2666014 T PT2666014 T PT 2666014T
- Authority
- PT
- Portugal
- Prior art keywords
- furazanobenzimidazoles
- tubulin
- biomarker
- glu
- drug response
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4245—Oxadiazoles
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
- G01N33/5026—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on cell morphology
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/44—Multiple drug resistance
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Cell Biology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Analytical Chemistry (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Food Science & Technology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Toxicology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Physiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Apparatus Associated With Microorganisms And Enzymes (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP11151681 | 2011-01-21 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PT2666014T true PT2666014T (pt) | 2016-12-22 |
Family
ID=43928137
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PT127004943T PT2666014T (pt) | 2011-01-21 | 2012-01-19 | Utilização de glu-tubulina como um biomarcador da resposta farmacológica a furazanobenzimidazolos |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US9995754B2 (pt) |
| EP (1) | EP2666014B1 (pt) |
| JP (1) | JP6270481B2 (pt) |
| CN (1) | CN103460042B (pt) |
| AU (1) | AU2012208516B2 (pt) |
| CA (2) | CA2822530C (pt) |
| DK (1) | DK2666014T3 (pt) |
| ES (1) | ES2608315T3 (pt) |
| HK (1) | HK1192323A1 (pt) |
| HU (1) | HUE031162T2 (pt) |
| PL (1) | PL2666014T3 (pt) |
| PT (1) | PT2666014T (pt) |
| WO (1) | WO2012098203A1 (pt) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2691533B1 (en) * | 2011-03-29 | 2017-04-05 | Basilea Pharmaceutica AG | Use of phospho-akt as a biomarker of drug response |
| US20180306790A1 (en) | 2015-10-22 | 2018-10-25 | Basilea Pharmaceutica International AG | Use of eb1 as a biomarker of drug response |
| US10170419B2 (en) * | 2016-06-22 | 2019-01-01 | International Business Machines Corporation | Biconvex low resistance metal wire |
| WO2018197475A1 (en) | 2017-04-26 | 2018-11-01 | Basilea Pharmaceutica International AG | Processes for the preparation of furazanobenzimidazoles and crystalline forms thereof |
| WO2018210868A1 (en) | 2017-05-16 | 2018-11-22 | Basilea Pharmaceutica International AG | Novel dosage principle for drugs useful for treating neoplastic diseases |
| US11419856B2 (en) | 2017-11-20 | 2022-08-23 | Basilea Pharmaceutica International AG | Pharmaceutical combinations for use in the treatment of neoplastic diseases |
| CN109053584B (zh) * | 2018-09-12 | 2022-03-18 | 南京大学 | 一类1，2-二芳基苯并咪唑衍生物的制备及其应用 |
| WO2022053549A1 (en) | 2020-09-10 | 2022-03-17 | Basilea Pharmaceutica International AG | Use of c-myc as a biomarker of drug response |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE315789T1 (de) * | 1999-11-16 | 2006-02-15 | Genentech Inc | Elisa für vegf |
| WO2004103994A1 (en) * | 2003-05-23 | 2004-12-02 | Basilea Pharmaceutica Ag | Furazanobenzimidazoles |
| CA2532722C (en) * | 2003-07-17 | 2016-10-04 | Pacific Edge Biotechnology, Ltd. | Cystatin sn (cst1) and other markers for detection of gastric cancer |
| WO2005098446A2 (en) * | 2004-03-31 | 2005-10-20 | The Johns Hopkins University | Biomarkers for ovarian cancer |
| US8193238B2 (en) * | 2006-03-08 | 2012-06-05 | University Of Maryland, Baltimore | Inhibition of microtubule protrusion in cancer cells |
| US20110165178A1 (en) * | 2007-01-23 | 2011-07-07 | Centre National De La Recherche Scientifique (Cnrs) | Diagnosis of prostate cancer |
| UA106763C2 (uk) | 2009-07-27 | 2014-10-10 | Базілеа Фармас'Ютіка Аг | Фуразанобензимідазоли як проліки для лікування пухлинних або аутоімунних захворювань |
-
2012
- 2012-01-19 CN CN201280005860.3A patent/CN103460042B/zh active Active
- 2012-01-19 WO PCT/EP2012/050814 patent/WO2012098203A1/en active Application Filing
- 2012-01-19 AU AU2012208516A patent/AU2012208516B2/en not_active Ceased
- 2012-01-19 CA CA2822530A patent/CA2822530C/en active Active
- 2012-01-19 EP EP12700494.3A patent/EP2666014B1/en active Active
- 2012-01-19 ES ES12700494.3T patent/ES2608315T3/es active Active
- 2012-01-19 HU HUE12700494A patent/HUE031162T2/en unknown
- 2012-01-19 DK DK12700494.3T patent/DK2666014T3/en active
- 2012-01-19 US US13/980,208 patent/US9995754B2/en active Active
- 2012-01-19 PT PT127004943T patent/PT2666014T/pt unknown
- 2012-01-19 CA CA3142744A patent/CA3142744A1/en not_active Abandoned
- 2012-01-19 PL PL12700494T patent/PL2666014T3/pl unknown
- 2012-01-19 JP JP2013549810A patent/JP6270481B2/ja active Active
-
2014
- 2014-06-13 HK HK14105637.2A patent/HK1192323A1/zh not_active IP Right Cessation
-
2018
- 2018-05-22 US US15/986,577 patent/US10656162B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| CA2822530C (en) | 2023-02-21 |
| WO2012098203A1 (en) | 2012-07-26 |
| US20140024686A1 (en) | 2014-01-23 |
| HK1192323A1 (zh) | 2014-08-15 |
| JP2014505876A (ja) | 2014-03-06 |
| US20180364254A1 (en) | 2018-12-20 |
| PL2666014T3 (pl) | 2017-07-31 |
| CN103460042B (zh) | 2015-12-02 |
| CN103460042A (zh) | 2013-12-18 |
| EP2666014B1 (en) | 2016-10-05 |
| US9995754B2 (en) | 2018-06-12 |
| CA3142744A1 (en) | 2012-07-26 |
| DK2666014T3 (en) | 2017-01-09 |
| JP6270481B2 (ja) | 2018-01-31 |
| US10656162B2 (en) | 2020-05-19 |
| NZ611525A (en) | 2015-06-26 |
| EP2666014A1 (en) | 2013-11-27 |
| ES2608315T3 (es) | 2017-04-07 |
| AU2012208516A1 (en) | 2013-06-20 |
| CA2822530A1 (en) | 2012-07-26 |
| HUE031162T2 (en) | 2017-07-28 |
| AU2012208516B2 (en) | 2015-11-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HK1244183A1 (zh) | Ivacaftor的氘化衍生物 | |
| EP2750635A4 (en) | REFERENCE TO RELATED APPLICATIONS | |
| GB201104096D0 (en) | Production of graphene | |
| HUE047354T2 (hu) | Ivacaftor deuterizált származékai | |
| HK1191096A1 (zh) | 乙酰化微管蛋白作為對呋咱並苯並咪唑類的藥物反應的生物標誌物的用途 | |
| HK1192323A1 (zh) | -微管蛋白作為對呋咱並苯並咪唑類的藥物反應的生物標誌物的用途 | |
| HK1189056A1 (zh) | 作為藥物對呋咱並苯並咪唑響應的生物標記的用途 | |
| HK1185947A1 (zh) | 作為呋咱並苯並咪唑類藥物應答的生物標記的用途 | |
| ZA201306520B (en) | Use of phospho-akt as a biomarker of drug response | |
| EP2773262A4 (en) | ASSESSMENT OF A CARDIAL STRUCTURE | |
| EP2776586A4 (en) | BIOMARKERS OF REACTION ON PROTEASOMAL INHIBITORS | |
| PL2753330T3 (pl) | Terapeutyczne zastosowania ektoiny | |
| GB2489486B (en) | Improvements relating to construction | |
| EP2683411A4 (en) | METHODS OF USING MICROARN-26A FOR PROMOTING ANGIOGENESIS | |
| HK1203355A1 (en) | Uses of 4-desferrithiocin analogs 4- | |
| EP2776043A4 (en) | BIOMARKERS OF REACTION ON PROTEASOMAL INHIBITORS | |
| EP2684869A4 (en) | PREPARATION OF 3-MERCAPOTOPROPIONATES | |
| EP2782902A4 (en) | DERIVATIVES FROM PHENOXYISOBUTTERIC ACID | |
| EP2791349A4 (en) | SYNTHESIS OF N-ACETYL-D-NEURAMIC ACID | |
| EP2702991A4 (en) | COMPOSITION OF ENTACOPONE | |
| HUE050880T2 (hu) | Fotokémiailag hasítható vegyületek alkalmazása | |
| GB201116456D0 (en) | Improvements relating to foorwear | |
| GB201106098D0 (en) | Production of fuels | |
| GB201209895D0 (en) | Use of a composition | |
| ZA201205358B (en) | Use of a salt of bistetrazolylamine |